Advertisement
Table 2 Clinicopathological characteristics of 342 metastatic breast cancer patients (MBC) with or without hand-foot syndrome (HFS)
| Characteristic | Total [cases (%)] | Patients with HFS [cases (%)] | Patients without HFS [cases (%)] |
|---|---|---|---|
| Age (years) | |||
| ≤ 40 | 57 (16.7) | 30 (8.8) | 27 (7.9) |
| > 40 | 285 (83.3) | 163 (47.7) | 122 (35.7) |
| Family history of cancera | |||
| None | 275 (80.4) | 152 (44.4) | 123 (36.0) |
| Breast cancer or ovarian cancer | 19 (5.6) | 8 (2.3) | 11 (3.2) |
| Other malignancies | 48 (14.0) | 33 (9.6) | 15 (4.4) |
| Menstrual station | |||
| Premenopause | 218 (63.7) | 120 (35.1) | 98 (28.7) |
| Postmenopause | 118 (34.5) | 71 (20.8) | 47 (13.7) |
| Unclear | 6 (1.8) | 2 (0.6) | 4 (1.2) |
| Clinical stage | |||
| I + II | 154 (45.0) | 89 (26.0) | 65 (19.0) |
| III | 143 (41.8) | 85 (24.9) | 58 (17.0) |
| IV | 14 (4.1) | 5 (1.5) | 9 (2.6) |
| Unclear | 31 (9.1) | 14 (4.1) | 17 (5.0) |
| Pathological type | |||
| Intraductal carcinoma | 4 (1.2) | 2 (0.6) | 2 (0.6) |
| Infiltrating ductal carcinoma | 306 (89.5) | 172 (50.3) | 134 (39.2) |
| Invasive lobular carcinoma | 17 (5.0) | 11 (3.2) | 6 (1.8) |
| Others | 11 (3.2) | 7 (2.0) | 4 (1.2) |
| Unclear | 4 (1.2) | 1 (0.3) | 3 (0.9) |
| Pathological grade | |||
| Grade 1 | 10 (2.9) | 8 (2.3) | 2 (0.6) |
| Grade 2–3 | 170 (49.7) | 96 (28.1) | 74 (21.6) |
| Unclear | 162 (47.4) | 89 (26.0) | 73 (21.3) |
| Vascular invasion | |||
| No | 308 (90.1) | 174 (50.9) | 134 (39.2) |
| Yes | 34 (9.9) | 19 (5.6) | 15 (4.4) |
| Axillary lymph node metastasis at initial diagnosis | |||
| No | 106 (31.0) | 54 (15.8) | 52 (15.2) |
| Yes | 225 (65.8) | 136 (39.8) | 89 (26.0) |
| Unclear | 11 (3.2) | 3 (0.9) | 8 (2.3) |
| Distant metastasis at initial diagnosis | |||
| No | 324 (94.7) | 186 (54.4) | 138 (40.4) |
| Yes | 14 (4.1) | 5 (1.5) | 9 (2.6) |
| Unclear | 4 (1.2) | 2 (0.6) | 2 (0.6) |
| ER status | |||
| Positive | 215 (62.9) | 123 (36.0) | 92 (26.9) |
| Negative | 117 (34.2) | 65 (19.0) | 52 (15.2) |
| Unclear | 10 (2.9) | 5 (1.5) | 5 (1.5) |
| PR status | |||
| Positive | 213 (62.3) | 117 (34.2) | 96 (28.1) |
| Negative | 118 (34.5) | 70 (20.5) | 48 (14.0) |
| Unclear | 11 (3.2) | 6 (1.8) | 5 (1.5) |
| HER2 status | |||
| Positive | 83 (24.3) | 47 (13.7) | 36 (10.5) |
| Negative | 230 (67.3) | 130 (38.0) | 100 (29.2) |
| Unclearb | 29 (8.5) | 16 (4.7) | 13 (3.8) |
| Therapy | |||
| Capecitabine | 20 (5.8) | 10 (2.9) | 10 (2.9) |
| Docetaxel plus capecitabine | 205 (59.9) | 123 (36.0) | 82 (24.0) |
| Vinorelbine plus capecitabine | 98 (28.7) | 48 (14.0) | 50 (14.6) |
| Othersc | 19 (5.6) | 12 (3.5) | 7 (2.0) |
| Therapy line | |||
| First-line | 211 (61.7) | 121 (35.4) | 90 (26.3) |
| Multi-line | 131 (38.3) | 72 (21.1) | 59 (17.3) |
| Metastatic site | |||
| No visceral metastasis (including local recurrence) | 104 (30.4) | 60 (17.5) | 44 (12.9) |
| Visceral metastasis | 238 (69.6) | 133 (38.9) | 105 (30.7) |
| Maintenance therapy | |||
| Yes | 137 (40.1) | 94 (27.5) | 43 (12.6) |
| No | 205 (59.9) | 99 (28.9) | 106 (31.0) |
| Response evaluation | |||
| CR | 7 (2.0) | 5 (1.5) | 2 (0.6) |
| PR | 194 (56.7) | 107 (31.3) | 87 (25.4) |
| SD | 90 (26.3) | 56 (16.4) | 34 (9.9) |
| PD | 39 (11.4) | 20 (5.8) | 19 (5.6) |
| Unclear | 12 (3.5) | 5 (1.5) | 7 (2.0) |
| Survival conditiond | |||
| Alive | 218 (63.7) | 124 (36.3) | 94 (27.5) |
| Dead | 124 (36.3) | 69 (20.2) | 55 (16.1) |
